

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/110649/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Wang, Eddie C. Y., Pjechova, Marina, Nightingale, Katie, Vlachava, Virginia-Maria, Patel, Mihil, Ruckova, Eva, Forbes, Simone K., Nobre, Luis, Antrobus, Robin, Roberts, Dawn, Fielding, Ceri A., Seirafian, Sepehr, Davies, James, Murrell, Isa, Lau, Betty, Wilkie, Gavin S., Suarez, Nicolas M., Stanton, Richard J., Vojtesek, Borivoj, Davison, Andrew, Lehner, Paul J., Weekes, Michael P., Wilkinson, Gavin W. G. and Tomasec, Peter 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. *Proceedings of the National Academy of Sciences* 115 (19), pp. 4998-5003. 10.1073/pnas.1720950115

Publishers page: <https://doi.org/10.1073/pnas.1720950115>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **Title Page**

2 **PNAS research report, direct submission**

3
4 **Classification:** - Biological Sciences
5 - Microbiology
6

7 **Suppression of co-stimulation by human cytomegalovirus promotes evasion of**
8 **cellular immune defenses**

9
10 **Short Title:** HCMV regulates CD58 to control T and NK cells
11

12 Eddie C.Y. Wang^{1*}, Mariana Pjechova^{1,2*}, Katie Nightingale³, Virginia-Maria Vlahava¹,
13 Mihil Patel¹, Eva Ruckova^{1,2}, Simone Forbes¹, Luis Nobre³, Robin Antrobus³, Dawn
14 Roberts¹, Ceri A. Fielding¹, Sepehr Seirafian¹, James Davies¹, Isa Murrell¹, Betty Lau⁴,
15 Gavin S. Wilkie⁴, Nicolás M. Suárez⁴, Richard J. Stanton¹, Borivoj Vojtesek², Andrew
16 Davison⁴, Paul J. Lehner³, Michael P. Weekes^{3*}, Gavin W.G. Wilkinson^{1*}, Peter
17 Tomasec^{†*}

18
19 ¹Cardiff University School of Medicine, Division of Infection and Immunity, Henry Wellcome
20 Building, Heath Park, Cardiff CF14 4XN, UK

21 ²Regional Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer
22 Institute, Zlutý Kopec 7, 65653 Brno, Czech Republic

23 ³Cambridge Institute for Medical Research, University of Cambridge, Hills Road,
24 Cambridge CB2 0XY, UK

25 ⁴ MRC-University of Glasgow Centre for Virus Research, Sir Michael Stoker Building, 464
26 Bearsden Road, Glasgow G61 1QH, UK

27
28 *these authors contributed equally to this study
29

30 **Corresponding Author:**

31 Eddie C. Y. Wang, Cardiff University School of Medicine, Division of Infection and
32 Immunity, Henry Wellcome Building 1F-07, Heath Park, Cardiff CF14 4XN, UK; +44-
33 2920687035; WangEC@cf.ac.uk
34

† deceased

1 **Keywords:**

2 HCMV, immune modulation, CTL, T-cell, NK cell, CD58, LFA3, CD2, UL148, UL/b'

3 **Abstract**

4 CD58 is an adhesion molecule that is known to play a critical role in co-stimulation of
5 effector cells and is intrinsic to immune synapse structure. Herein, we describe the first
6 virally-encoded gene that inhibits CD58 surface expression. Human cytomegalovirus
7 (HCMV) UL148 was necessary and sufficient to promote intracellular retention of CD58
8 during HCMV infection. Blocking studies with antagonistic anti-CD58 mAb and an HCMV
9 UL148 deletion mutant (HCMV Δ UL148) with restored CD58 expression demonstrated that
10 the CD2/CD58 axis was essential for the recognition of HCMV-infected targets by
11 CD8⁺ HCMV-specific cytotoxic T lymphocytes (CTLs). Further, challenge of peripheral
12 blood mononuclear cells *ex vivo* with HCMV Δ UL148 increased both CTL and natural killer
13 (NK) cell degranulation against HCMV-infected cells, including NK-driven antibody-
14 dependent cellular cytotoxicity, showing that UL148 is a modulator of the function of
15 multiple effector cell subsets. Our data stress the impact of HCMV immune evasion
16 functions on shaping the immune response, highlighting the capacity for their potential use
17 in modulating immunity during the development of anti-HCMV vaccines and HCMV-based
18 vaccine vectors.

19

20 **Significance statement**

21 HCMV is the major infectious cause of developmental disorders in babies due to its
22 capacity to cross the placenta. HCMV is also a major pathogen in transplant recipients
23 and HIV-AIDS patients. Despite inducing the strongest immune responses observed for
24 any human pathogen, HCMV evades host defenses and persists for life. We report a novel
25 viral stealth strategy. HCMV UL148 reduces surface expression of a key cell adhesion
26 molecule (CD58), impairing the ability of NK and T cells to be activated by HCMV-infected
27 cells. This is the first description of a viral gene targeting this pathway. Our findings
28 highlight a role for CD58 in recognition of HCMV-infected cells and may be relevant for
29 development of future antiviral therapies.

30

1 \body

2 **Introduction**

3 Human cytomegalovirus (HCMV; species *Human betaherpesvirus 5*), is the major viral
4 cause of congenital birth defects and an important pathogen capable of causing severe
5 disease in immunocompromised and immune-naïve individuals. HCMV is noted for
6 inducing the most potent cellular immune responses observed for any human pathogen.
7 These responses, including expansions of cytotoxic T-lymphocytes (CTLs) and natural
8 killer (NK) cells of a specific phenotype, are large and are maintained for life (reviewed in
9 (1, 2)). HCMV, however, is not cleared by the host following primary infection. The
10 mechanisms that underpin the ability of the virus to endure in the presence of such
11 immunity has been the target of intense study, with the hope that the knowledge gained
12 will inform the generation of anti-HCMV vaccines and also vaccine design, for which the
13 maintenance of induced immune responses is paramount. Indeed, HCMV is being pursued
14 as a vaccine vector in its own right as redirection of anti-CMV immunity can clear
15 pathogens otherwise capable of persisting in their host (3, 4). The study of HCMV-encoded
16 genes and proteins has revealed many strategies designed to avoid innate and adaptive
17 immunity, which have defined a number of basic immune pathways essential to CTL and
18 NK activity. These include at least four functions that inhibit HLA-I expression and ten that
19 impair NK cell activation (reviewed in (5, 6)).

20

21 CTLs and NK cells use the supramolecular adhesion complex (SMAC) at the immune
22 synapse (IS) to interact with their targets. The SMAC is a tightly packed intercellular
23 complex of adhesion molecules and receptor/ligand pairs where antigen presentation and
24 signaling take place, which regulate the secretion of cytotoxic granules and cytokines from
25 the effector cells (7-9). There are many descriptions of HCMV acting to prevent expression
26 of activating ligands and promote the expression of inhibitory receptors on the target cell
27 surface, but reports of immune evasion mechanisms able to impede formation of IS
28 structure have been limited to remodeling of the target cell actin cytoskeleton (10).

29

30 CD58 (LFA-3) on target cells acts to promote cell-to-cell adhesion and IS formation, and
31 to provide a co-stimulatory signal through its receptor, CD2, on effectors (11-23). Recent
32 studies have highlighted the importance of CD2 engagement for co-stimulation of CD4⁺ T-
33 cells in HCMV infection (24) and adaptive NK cells (25, 26), and have identified the
34 CD2/CD58 axis as the primary co-stimulatory pathway for CD28⁺CD8⁺ CTLs (19, 27, 28).
35 Cell surface expression of CD58 has been reported to be either upregulated (29, 30) or
36 downregulated (31) by HCMV infection depending on the HCMV strain used. The aim of

1 our study was to dissect this phenomenon, thereby determining the functional relevance
2 of regulating CD58 expression on HCMV-infected cells. We describe the identification of
3 the first viral-encoded gene responsible for downregulating CD58 and detail the broad
4 impact of this novel function on both CTL and NK cell recognition in the context of HCMV
5 infection.

6

1 **Results**

2

3 **HCMV UL148 is a novel viral function down-regulating cell surface expression of** 4 **CD58**

5 HCMV strain AD169 has previously been reported to upregulate CD58 (29, 30), whereas
6 proteomic analysis with low passage HCMV strain Merlin has suggested the opposite (31).
7 We confirmed these effects directly by flow cytometry (Fig.1). AD169 has suffered a
8 spontaneous deletion in its genome during *in vitro* culture, involving a 15kb sequence
9 designated the U_L/b' region (32). We therefore investigated whether the function
10 responsible for CD58 downregulation resided within U_L/b'. Surface expression of CD58
11 was analyzed in cells infected with a complete library of HCMV strain Merlin U_L/b' single
12 gene deletion mutants (loss of function screen, Fig .2A) and an adenovirus vector library
13 over-expressing each U_L/b' gene individually (gain of function screen, Fig.2B, Fig.S1).
14 Both screens identified HCMV UL148 as the gene responsible, with loss of UL148 from
15 HCMV strain Merlin (referred to as HCMV Δ UL148) (Fig.S2) resulting in CD58 upregulation
16 (Fig.2A, C), and ectopic expression of UL148 resulting in CD58 downregulation (Fig.2B,
17 D).

18

19 To screen for additional cell surface targets of UL148, we used plasma membrane profiling
20 (PMP) of cells infected with HCMV, comparing Merlin to HCMV Δ UL148. Filtering for
21 proteins with Ig-, MHC, Cadherin, C-type lectin and TNF InterPro functional domains (31,
22 33) was used to extend interrogation of UL148, focusing the analysis on immune receptors
23 and ligands directly involved in NK or CTL functions (Fig.2E, Dataset S1 'Summary'). This
24 proteomic analysis identified CD58 as the only cell surface molecule targeted by UL148
25 that fell within these categories (Fig.2E).

26

27 **CD58 is retained within the cell by UL148**

28 Expression of CD58 was then studied during the course of HCMV infection. CD58 was
29 gradually downregulated from the cell surface (Fig.1), whereas expression increased in
30 whole cell lysates (Fig.3A). A faster migrating EndoH-sensitive CD58 glycoform
31 accumulated in HCMV-infected cells and contrasted with the EndoH-resistant form
32 detected in cells infected with HCMV Δ UL148 (Fig.3A & B). This result is consistent with
33 UL148 retaining CD58 as an immature precursor in the ER prior to processing through the
34 Golgi complex. This model was further supported by co-immunoprecipitation of CD58 with
35 UL148 from infected cells visualized either using immunoprecipitation with V5-tagged
36 UL148 and Western blotting with anti-CD58 (Fig.3C) or in a global proteomic analysis

1 using stable isotope labeling by amino acids in cell culture and immunoprecipitation
2 (SILAC-IP) (Fig.S3). In conclusion, UL148 was both necessary and sufficient to mediate
3 cell surface down-regulation and intracellular retention of CD58.

4

5 **UL148 is a potent modulator of CTL function**

6 The functional impact of CD58 regulation on CTL recognition was investigated in the
7 context of HCMV infection by using HLA-A2-restricted CD8⁺ CTL lines generated to
8 HCMV-IE1 VLEETSMVL (VLE) and HCMV-pp65 NLVPMVATV (NLV) peptides. These
9 lines were tested by using CD107a degranulation assays and intracellular cytokine
10 staining to detect cytokine production against autologous fibroblasts (uninfected or
11 infected with Merlin or HCMV Δ UL148) pulsed with a range of peptide concentrations.
12 Absence of peptide led to minimal CTL activation. Peptide pulsing of uninfected cells
13 resulted in a large increase in degranulation, which was significantly impaired by infection
14 with HCMV strain Merlin. Deletion of UL148 resulted in recovery of degranulation in both
15 CTL lines against HCMV-infected fibroblasts, including some experiments in which
16 activation by HCMV Δ UL148 was equivalent to that observed by peptide-pulsed uninfected
17 cells (Fig.4A). A similar effect was observed for cytokine production in a third CTL line
18 (Fig.S4). This occurred even though both Merlin and HCMV Δ UL148 down-regulated HLA
19 class-I evenly by more than tenfold (Fig.4B), indicating that these effects were independent
20 of signals supplied through TCR recognition of HLA-I at that peptide dose. UL148 function
21 could therefore compensate for more than tenfold differences in HLA-I expression.
22 Significant differences in degranulation between Merlin and HCMV Δ UL148 were observed
23 over a narrow peptide range, with close to a doubling of the proportion of activated CD8⁺
24 CTLs occurring at 1 μ g/ml peptide, corresponding to a molar concentration of ~1 μ M.
25 Doubling or decreasing the peptide dose by 20-fold overcame these differences (Fig.4C).

26

27 **CD58 co-stimulatory function occurs only in HCMV-infected cells**

28 The specificity of the UL148 effect on CD58 was explored by using a monoclonal antibody
29 (mAb) that inhibited CD2/CD58 interaction. Application of anti-CD58 mAb resulted in
30 significant blocking of CTL activity towards cells infected with HCMV Δ UL148 over a range
31 of peptide concentrations, in some cases reducing it to the levels observed when using
32 Merlin-infected cells as targets (Fig.4D). We performed a more detailed analysis that
33 combined all blocking experiments by normalizing data to the isotype control in each
34 experiment. These combined data showed that blocking of CD58 produced an effect that
35 was observable even against Merlin-infected targets, that became significantly different
36 from the blocking of activation by HCMV Δ UL148 at the peak peptide concentration

1 (1µg/ml) (Fig.4E). Irrespective of higher levels of surface CD58 compared to HCMV-
2 infected targets, CTL activation measured by CD107 degranulation against uninfected
3 cells could not be reduced by anti-CD58 mAb treatment, regardless of the peptide
4 concentration used (Fig.4E,F). This differential effect of peptide loading and targets implies
5 that HCMV-specific CD8⁺ CTLs are exquisitely sensitive to the context in which they
6 receive activation signals, in that CD58-mediated co-stimulation became relevant only
7 when these CTL were faced with an HCMV-infected target.

8

9 **UL148 significantly alters the *ex vivo* PBMC response to HCMV-infected cells**

10 The above data were generated using *in vitro* expanded T-cell lines. To test function in a
11 more physiologically relevant setting, we challenged peripheral blood mononuclear cells
12 (PBMC) *ex vivo* with fibroblasts infected with either Merlin or HCMV Δ UL148 in the absence
13 of exogenous peptide, comparing the degranulation responses of key effector cell subsets
14 to the two viruses. In autologous assays and in the absence of peptide, CD3⁺CD8⁺ T-cells
15 significantly increased their activation in response to HCMV Δ UL148 in 3 of 9 subjects
16 (Fig.4G). The CD2/CD58 axis has also been reported to be important in the activation of
17 'adaptive' NK cells defined through expression of CD57 and NKG2C, the expansion of
18 which is associated with previous HCMV infection (25, 26). Responses of *ex vivo* NK cells
19 were tested in the presence of Cytotect (purified IgG from HCMV-seropositive subjects) or
20 IgG from HCMV-seronegative individuals, included as a negative control to measure
21 antibody-dependent cellular cytotoxicity (ADCC) as well as standard NK cell function. NK
22 cell function was measured against both allogeneic human fetal foreskin fibroblasts
23 (HFFFs) and autologous HCMV-infected skin fibroblasts. The greatest effect of removing
24 UL148 was observed in an allogeneic ADCC setting with smaller, but significant increases
25 in NK cell activation in the absence of Cytotect (Fig.5A,B, Fig.S4). In an autologous setting,
26 removing UL148 significantly increased the recognition of HCMV-infected targets only in
27 the presence of Cytotect (Fig.5C). Further analysis to phenotype the responsive subset
28 indicated it resided in CD57⁺ NK cells (Fig.5D), with different subjects showing significantly
29 different responses to Δ UL148 in one, other or both of CD57⁺NKG2C⁻ and CD57⁺NKG2C⁺
30 NK populations (Fig.5E). CD57⁻NKG2C⁺ populations were not analyzed because they
31 represented less than 3% of total CD3⁻CD56⁺ NK cells in all but one subject.

1 Discussion

2
3 HCMV has become a paradigm for viral immune evasion, with the study of the activities of
4 its genes and proteins unveiling many aspects of immune function. We have now identified
5 HCMV UL148 as the first recognized virally encoded downregulator of the cell adhesion
6 molecule CD58, the intracellular retention of which reduces *ex vivo* activation of both CTLs
7 and NK cells. This function is compatible with UL148 being an ER-resident type 1
8 transmembrane glycoprotein containing an ER retention motif (RRR, at residues 314-316)
9 (34, 35). The CD58/CD2 axis may become particularly important when infected target cells
10 exhibit sub-optimal activation signals, for example due to the action of multiple HCMV-
11 encoded immune evasins.

12
13 To date, UL148 has only been assigned one other viral function. In the HCMV strain
14 TB40/E, UL148 disruption alters the ratio of glycoprotein H/glycoprotein L (gH/gL)
15 complexes involved in virus entry, resulting in increased infectivity of epithelial cells, in part
16 due to a direct interaction between UL148 and those complexes, and most likely in the ER
17 (34). Our SILAC-IP analysis of proteins binding UL148 during infection with HCMV strain
18 Merlin did not demonstrate a specific interaction with gH or gL (Fig.S3), suggesting
19 underlying complexity in UL148 interactions associated with the HCMV strains used and
20 their cellular tropisms. In this regard, there is also the possibility that the host proteins
21 targeted by UL148 may differ depending on the cell type infected by HCMV, with our data
22 derived from fibroblasts. The rhesus cytomegalovirus (RhCMV)-encoded ortholog of
23 UL148 (Rh159) also has effects on virus tropism, although in this case disruption of the
24 gene renders the virus unable to spread in epithelial cells (36). Further Rh159 exhibits
25 immune regulatory functions, impairing the surface expression of the NKG2D ligands,
26 MICA, MICB, ULBP1 and ULBP2 (37). Interestingly, although both Rh159 and UL148 act
27 by binding to, and retaining intracellularly their target proteins, we and others have shown
28 that UL148 does not bind any NKG2D ligands (37). In HCMV, these ligands are targeted
29 by UL16, UL142, US9, US18 and US20 (5, 38). It will be interesting to determine whether
30 there is a common theme of CMV-encoded ER-resident proteins that impact on both
31 immune evasion and cell tropism.

32
33 It is intriguing that blocking the CD2/CD58 interaction with an anti-CD58 monoclonal
34 antibody did not inhibit effector activation by uninfected peptide-pulsed target cells, but did
35 inhibit activation by HCMV-infected cells (Fig. 4D-F). A degree of inhibition of Merlin-
36 infected targets was expected since CD58 was still present albeit at a reduced level

1 compared to HCMV Δ UL148-infected cells (Fig.4B). The absence of any effect against
2 uninfected targets (which had equivalent levels of CD58 to HCMV Δ UL148-infected cells)
3 is surprising. The multiple immune evasion mechanisms employed by HCMV, such as
4 impairment of TCR signaling via HLA-I downregulation or via inhibitory receptors such as
5 LIR-1 binding HCMV UL18 (39), alter the balance of activating and inhibitory signals
6 received by effectors. Our data are consistent with the concept that there is much more
7 complexity in the way CD8⁺ CTLs are activated by virally infected targets. HCMV-specific
8 CTLs may be 're-tuned' to activate when exposed to infected targets in response to virus-
9 encoded modulation of multiple activating and inhibitory ligands.

10

11 Some speculative evidence for this idea may be gleaned from the phenotype of HCMV-
12 specific CTLs *in vivo*. HCMV drives massive, stable CD8⁺ CTL expansions, but it is
13 interesting to note that the detailed phenotype and responsiveness of these cells is
14 unusual compared to those described in classical models of T-cell differentiation (reviewed
15 recently in (1)). For example, continuous *in vitro* stimulation by anti-CD3/anti-CD28 beads
16 induces hallmarks of exhaustion in CD8⁺ T-cells (IL-7R^{lo}; and high levels of the immune
17 cell inhibitor, programmed cell death protein 1 (PD1) (40)) that are reduced by co-
18 stimulation through anti-CD2 signals (28). In contrast, although HCMV-specific CD8⁺ CTLs
19 have been reported as showing an exhausted/senescent and/or terminally differentiated
20 phenotype, they exhibit proliferative capacity, the ability to change co-stimulatory and
21 chemokine receptor-phenotype (41, 42) and do not show all the functionally associated
22 classical markers of exhaustion such as PD1. They are generally PD1^{lo} (39), whereas
23 HCMV increases PD-L1 expression on infected cells (31), which would be consistent with
24 HCMV-specific CTLs adapting to receive fewer inhibitory signals through the PD1/PD-L1
25 axis.

26

27 It is possible that immune adaptation occurs in all effector cells facing HCMV-infected
28 targets, and that this leads to the unusual effector phenotypes observed in HCMV-
29 seropositive subjects. With regard to NK cells, an 'adaptive' NK subset that is
30 CD57⁺NKG2C⁺FceR1⁻ is expanded in HCMV-infected individuals and involved in ADCC
31 (43, 44). *In vitro* expanded NKG2C⁺ NK cells exhibit higher levels of CD2 expression (45),
32 which could aid activation in the face of lower levels of CD58 on target cells. We found
33 that CD57⁺ NK cells exhibited enhanced ADCC in response to targets infected with
34 HCMV Δ UL148 compared to Merlin, with different subjects showing an impact on either or
35 both NKG2C⁻ and NKG2C⁺ NK cells within the CD57⁺ population (Fig.5). This is not
36 unexpected, as NKG2C null individuals show CD57⁺ NK expansions following HCMV

1 infection (2), which exhibit a requirement for CD2 co-stimulation in their responses (26).
2 The data are consistent with expanded effector subsets in HCMV-seropositive individuals
3 showing greater responsiveness to an activation pathway being inhibited by HCMV.
4
5 Beyond CTL and NK cell recognition, it is notable that HCMV infection specifically induces
6 cell surface expression of intercellular adhesion molecule 1 (ICAM1), which is reported to
7 have an involvement equivalent to that of CD58 in formation of the SMAC (31, 46, 47). In
8 the context of differential expression of such adhesion molecules. It is also tempting to
9 speculate that ICAM1 may play an essential separate function in HCMV biology, and the
10 specific downregulation of CD58 might provide an elegant mechanism for compensating
11 for ICAM1 induction on infected cells. Indeed, ICAM1 is important in facilitating endothelial
12 transmigration and permeability, and its induction could enhance dissemination of virus
13 through host tissues (48) or play a role in direct cell-to-cell transfer of virus (49).
14
15 Finally, our data highlights that significant *ex vivo* ADCC does occur against HCMV-
16 infected cells, even with HCMV strain Merlin, which encodes many NK cell immune
17 evasion mechanisms and multiple Fc binding proteins (50). The impact of deleting UL148
18 on ADCC and general immune responses suggest that HCMV might be manipulated to
19 drive the activation of multiple different effector cell types, making the emerging field of
20 HCMV-based vector design all the more important for vaccine development.
21

1 **Materials and Methods**

2

3 **Cells**

4 Human fetal foreskin fibroblasts immortalized with human telomerase (HF-TERT), HF-
5 TERTs transfected with the coxsackie-adenovirus receptor (HF-CAR), and TERT-
6 immortalized donor dermal fibroblasts have been described previously (10). Cells were
7 maintained in DMEM/10% fetal calf serum at 37°C/5% CO₂.

8

9 **Viruses**

10 HCMV strain Merlin RCMV1111/KM192298 (RL13⁻, UL128⁻) (51), AD169
11 varUK/BK000394, and Merlin recombinants containing single gene deletions in UL/b' were
12 generated as described previously (51) (SI1). Tagged HCMV recombinants were
13 generated as described previously (38, 52) (SI1). Recombinant adenovirus vectors
14 expressing individual HCMV UL/b' genes were generated as described previously (53)
15 and validated for expression (54).

16

17 **Antibodies and other reagents**

18 All reagentss were obtained from Biolegend, except Aqua live/dead dye (ThermoFisher),
19 CD3-PE-Cy7 (clone UCHT-1, Beckman Coulter), CD8-APC-H7 (clone SK1, BD
20 Biosciences), CD56-PE (clone N901, Beckman Coulter), CD58 (Abcam) CD107a-FITC
21 (clone H4A3, BD Biosciences), MHC class-I (clone W6/32, Serotec) NKG2C-PE (clone
22 134591, R&D systems), CD155 (5D1, (55)), actin (Sigma), V5-agarose (Abcam), V5
23 (Serotec), anti-mouse-AF647 (ThermoFisher), anti-mouse-HRP (BioRad), anti-rabbit-HRP
24 (BioRad), mouse IgG, UL141 (56), EndoH (NEB), PNGaseF (NEB). Other reagents were
25 CD8-APC (clone HIT8a), CD56-BV605 (clone HCD56), CD57-APC (clone HNK-1), CD58
26 (clone TS2/9), CD107a-PerCP-Cy5.5 (clone H4A3), TNF α -BV421 (clone Mab11), IFN γ -
27 PE-Cy7 (4S.B3), MHC class-I-PE (clone W6/32).

28

29 **Flow cytometry**

30 For HCMV infections, adherent cells were harvested with TripLE Express (Thermofisher)
31 or HyQTaseTM (GE Healthcare), stained in PBS/1%BSA buffer at 4°C with relevant
32 antibodies, fixed with 4% paraformaldehyde and analyzed on an Accuri C6 flow cytometer
33 (BD Biosciences) and with Accuri C6 software. For CD107a degranulation assays, data
34 were gathered on an 11-color Attune NxT flow cytometer (ThermoFisher) and analyzed
35 using Attune NxT or FlowJo V10 software.

36

1 **Immunoblotting**

2 Cells were lysed and boiled in reducing denaturing Nu-PAGE lysis buffer, and protein
3 samples were separated on Nu-PAGE gels, transferred onto nitrocellulose membrane (GE
4 Life Sciences), stained with relevant antibodies and Supersignal West Pico
5 chemiluminescent substrate and imaged on Hyperfilm-MP (GE Life Sciences). In co-
6 immunoprecipitation experiments, cells were lysed in Triton X-100 lysis buffer, and protein
7 complexes were captured with V5-agarose prior to SDS-PAGE and immunoblotting.

8

9 **NK and T-cell assays**

10 HCMV-specific CTL lines were grown from PBMCs stimulated with irradiated (6000 RADs)
11 autologous, peptide-coated fibroblasts as described previously (10). Degranulation assays
12 were performed as described previously (57), using effector:target ratios of 10:1. The
13 targets were pulsed with peptide at various concentrations and the excess washed off,
14 while for blocking studies, a final concentration of 10 µg/ml anti-CD58 mAb, TS2/9, was
15 used. Statistical testing of data was carried out by using Graphpad Prism 5.0 for ANOVAs
16 with Tukey's multiple comparisons post-tests; $p < 0.05$ was considered significant. Assays
17 detecting *ex vivo* PBMC responses were carried out as described previously (58), with
18 adaptation to a CD107a degranulation readout as described (57) and using multicolor flow
19 cytometry to identify responding CD3⁺CD8⁺ T-cells, CD3⁻CD56⁺ NK cells and populations
20 defined by expression of CD57 and NKG2C. Cytotect (Biotest) or IgG purified from HCMV-
21 seronegative subjects was incubated with targets for 10 mins at 37°C at a concentration
22 of 100 µg/ml prior to addition of an equivalent volume of effectors.

23

24 **Proteomics**

25 Proteomics was performed as described previously (31). Briefly, plasma membrane
26 glycoproteins were oxidized with sodium metaperiodate and then biotinylated with
27 aminoxybiotin (Cambridge Bioscience) prior to lysis of cells with Triton X-100. Biotinylated
28 glycoproteins were captured with streptavidin agarose, and then washed, denatured,
29 alkylated and digested on beads with Trypsin (Gibco). Peptides were fractionated by using
30 strong cation exchange. Enriched peptides were labeled with tandem mass tag (TMT)
31 reagents, combined at a 1:1 ratio, and then pre-fractionated by offline high-pH-reversed-
32 phase chromatography (Agilent). Mass spectrometry and data analysis were performed
33 as described previously by using an Orbitrap Fusion. P-values were estimated using
34 Benjamini-Hochberg-corrected significance A or Significance B values from Perseus
35 version 1.2.0.16 (59). SILAC-IP experiments were conducted and analyzed as described
36 previously (10).

1

2 **Ethics statement**

3 Healthy adult volunteers provided blood and dermal fibroblasts for this study after
4 providing written informed consent. The study was approved by the Cardiff University
5 School of Medicine Research Ethics Committee ref. nos: 10/20 and 16/52.

6

7 **Acknowledgements**

8 The study was supported by MRC and Wellcome Trust grants G1000236, MR/P001602/1,
9 WT090323MA, MR/L008734/1 (ECYW, VV, SF, DR, CAF, SS, IM, MiP, RJS, GWW, PT),
10 MC_UU_12014/3 (GSW, NMS, BL, AD), MEYS – NPS I – LO1413 (MP, ER), Czech
11 Science Foundation project no. P206/12/G151 (BV), Wellcome Trust Senior Clinical
12 Research Fellowship 108070 (MPW), and Wellcome Trust Principal Research Fellowship
13 101835 (PJL).

14

1 References

- 2 1. Klenerman P & Oxenius A (2016) T cell responses to cytomegalovirus. *Nat Rev*
3 *Immunol* 16(6):367-377.
- 4 2. Goodier MR, *et al.* (2014) Rapid NK cell differentiation in a population with near-
5 universal human cytomegalovirus infection is attenuated by NKG2C deletions. *Blood*
6 124(14):2213-2222.
- 7 3. Hansen SG, *et al.* (2013) Cytomegalovirus vectors violate CD8+ T cell epitope
8 recognition paradigms. *Science* 340(6135):1237874.
- 9 4. Hansen SG, *et al.* (2013) Immune clearance of highly pathogenic SIV infection. *Nature*
10 502(7469):100-104.
- 11 5. Wilkinson GW, *et al.* (2008) Modulation of natural killer cells by human
12 cytomegalovirus. *J Clin Virol* 41(3):206-212.
- 13 6. Halenius A, Gerke C, & Hengel H (2015) Classical and non-classical MHC I molecule
14 manipulation by human cytomegalovirus: so many targets-but how many arrows in
15 the quiver? *Cell Mol Immunol* 12(2):139-153.
- 16 7. Davis DM, *et al.* (1999) The human natural killer cell immune synapse. *Proc Natl Acad*
17 *Sci U S A* 96(26):15062-15067.
- 18 8. Grakoui A, *et al.* (1999) The immunological synapse: a molecular machine controlling
19 T cell activation. *Science* 285(5425):221-227.
- 20 9. Monks CR, Freiberg BA, Kupfer H, Sciaky N, & Kupfer A (1998) Three-dimensional
21 segregation of supramolecular activation clusters in T cells. *Nature* 395(6697):82-86.
- 22 10. Stanton RJ, *et al.* (2014) HCMV pUL135 remodels the actin cytoskeleton to impair
23 immune recognition of infected cells. *Cell Host Microbe* 16(2):201-214.
- 24 11. Beyers AD, Spruyt LL, & Williams AF (1992) Molecular associations between the T-
25 lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and
26 CD5. *Proc Natl Acad Sci U S A* 89(7):2945-2949.
- 27 12. Bierer BE & Hahn WC (1993) T cell adhesion, avidity regulation and signaling: a
28 molecular analysis of CD2. *Semin Immunol* 5(4):249-261.
- 29 13. Brown MH, Cantrell DA, Brattsand G, Crumpton MJ, & Gullberg M (1989) The CD2
30 antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface
31 of human T lymphocytes. *Nature* 339(6225):551-553.
- 32 14. Davis SJ, Ikemizu S, Wild MK, & van der Merwe PA (1998) CD2 and the nature of
33 protein interactions mediating cell-cell recognition. *Immunol Rev* 163:217-236.
- 34 15. Dustin ML, Selvaraj P, Mattaliano RJ, & Springer TA (1987) Anchoring mechanisms for
35 LFA-3 cell adhesion glycoprotein at membrane surface. *Nature* 329(6142):846-848.
- 36 16. Gassmann M, Amrein KE, Flint NA, Schraven B, & Burn P (1994) Identification of a
37 signaling complex involving CD2, zeta chain and p59fyn in T lymphocytes. *Eur J*
38 *Immunol* 24(1):139-144.
- 39 17. Holter W, Schwarz M, Cerwenka A, & Knapp W (1996) The role of CD2 as a regulator
40 of human T-cell cytokine production. *Immunol Rev* 153:107-122.
- 41 18. Kaizuka Y, Douglass AD, Vardhana S, Dustin ML, & Vale RD (2009) The coreceptor CD2
42 uses plasma membrane microdomains to transduce signals in T cells. *J Cell Biol*
43 185(3):521-534.
- 44 19. Leitner J, Herndler-Brandstetter D, Zlabinger GJ, Grubeck-Loebenstien B, &
45 Steinberger P (2015) CD58/CD2 Is the Primary Costimulatory Pathway in Human
46 CD28-CD8+ T Cells. *J Immunol* 195(2):477-487.
- 47 20. Meuer SC, *et al.* (1984) An alternative pathway of T-cell activation: a functional role
48 for the 50 kd T11 sheep erythrocyte receptor protein. *Cell* 36(4):897-906.
- 49 21. Selvaraj P, *et al.* (1987) The T lymphocyte glycoprotein CD2 binds the cell surface
50 ligand LFA-3. *Nature* 326(6111):400-403.

- 1 22. Siliciano RF, Pratt JC, Schmidt RE, Ritz J, & Reinherz EL (1985) Activation of cytolytic
2 T lymphocyte and natural killer cell function through the T11 sheep erythrocyte
3 binding protein. *Nature* 317(6036):428-430.
- 4 23. Yang JJ, Ye Y, Carroll A, Yang W, & Lee HW (2001) Structural biology of the cell
5 adhesion protein CD2: alternatively folded states and structure-function relation. *Curr*
6 *Protein Pept Sci* 2(1):1-17.
- 7 24. Shiao SL, *et al.* (2007) Human effector memory CD4+ T cells directly recognize
8 allogeneic endothelial cells in vitro and in vivo. *J Immunol* 179(7):4397-4404.
- 9 25. Rolle A, *et al.* (2016) CD2-CD58 interactions are pivotal for the activation and function
10 of adaptive natural killer cells in human cytomegalovirus infection. *Eur J Immunol*
11 46(10):2420-2425.
- 12 26. Liu LL, *et al.* (2016) Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell
13 Responses Revealed in NKG2C-Deficient Humans. *Cell Rep* 15(5):1088-1099.
- 14 27. Bruns T, *et al.* (2015) CMV infection of human sinusoidal endothelium regulates
15 hepatic T cell recruitment and activation. *J Hepatol* 63(1):38-49.
- 16 28. McKinney EF, Lee JC, Jayne DR, Lyons PA, & Smith KG (2015) T-cell exhaustion, co-
17 stimulation and clinical outcome in autoimmunity and infection. *Nature*
18 523(7562):612-616.
- 19 29. Grundy JE & Downes KL (1993) Up-regulation of LFA-3 and ICAM-1 on the surface of
20 fibroblasts infected with cytomegalovirus. *Immunology* 78(3):405-412.
- 21 30. Fletcher JM, Prentice HG, & Grundy JE (1998) Natural killer cell lysis of
22 cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell
23 surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with
24 the CMV-induced down-regulation of cell surface class I HLA. *J Immunol* 161(5):2365-
25 2374.
- 26 31. Weekes MP, *et al.* (2014) Quantitative temporal viromics: an approach to investigate
27 host-pathogen interaction. *Cell* 157(6):1460-1472.
- 28 32. Cha TA, *et al.* (1996) Human cytomegalovirus clinical isolates carry at least 19 genes
29 not found in laboratory strains. *J Virol* 70(1):78-83.
- 30 33. Vivier E, Tomasello E, Baratin M, Walzer T, & Ugolini S (2008) Functions of natural
31 killer cells. *Nat Immunol* 9(5):503-510.
- 32 34. Li G, Nguyen CC, Ryckman BJ, Britt WJ, & Kamil JP (2015) A viral regulator of
33 glycoprotein complexes contributes to human cytomegalovirus cell tropism. *Proc Natl*
34 *Acad Sci U S A* 112(14):4471-4476.
- 35 35. ELM (2015) The Eukaryotic Linear Motif resource for functional sites in proteins.
- 36 36. Lilja AE, Chang WL, Barry PA, Becerra SP, & Shenk TE (2008) Functional genetic
37 analysis of rhesus cytomegalovirus: Rh01 is an epithelial cell tropism factor. *J Virol*
38 82(5):2170-2181.
- 39 37. Sturgill ER, *et al.* (2016) Natural Killer Cell Evasion Is Essential for Infection by Rhesus
40 Cytomegalovirus. *PLoS Pathog* 12(8):e1005868.
- 41 38. Fielding CA, *et al.* (2014) Two novel human cytomegalovirus NK cell evasion functions
42 target MICA for lysosomal degradation. *PLoS Pathog* 10(5):e1004058.
- 43 39. Hertoghs KM, *et al.* (2010) Molecular profiling of cytomegalovirus-induced human
44 CD8+ T cell differentiation. *J Clin Invest* 120(11):4077-4090.
- 45 40. Francisco LM, Sage PT, & Sharpe AH (2010) The PD-1 pathway in tolerance and
46 autoimmunity. *Immunol Rev* 236:219-242.
- 47 41. Gandhi MK, *et al.* (2003) Late diversification in the clonal composition of human
48 cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell
49 transplantation. *Blood* 102(9):3427-3438.
- 50 42. Waller EC, *et al.* (2007) Differential costimulation through CD137 (4-1BB) restores
51 proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI))
52 CD8(+) T cells. *Blood* 110(13):4360-4366.

- 1 43. Guma M, *et al.* (2004) Imprint of human cytomegalovirus infection on the NK cell
2 receptor repertoire. *Blood* 104(12):3664-3671.
- 3 44. Guma M, *et al.* (2006) Expansion of CD94/NKG2C+ NK cells in response to human
4 cytomegalovirus-infected fibroblasts. *Blood* 107(9):3624-3631.
- 5 45. Beziat V, *et al.* (2013) NK cell responses to cytomegalovirus infection lead to stable
6 imprints in the human KIR repertoire and involve activating KIRs. *Blood*
7 121(14):2678-2688.
- 8 46. Kronschnabl M & Stamminger T (2003) Synergistic induction of intercellular adhesion
9 molecule-1 by the human cytomegalovirus transactivators IE2p86 and pp71 is
10 mediated via an Sp1-binding site. *J Gen Virol* 84(Pt 1):61-73.
- 11 47. Huppa JB & Davis MM (2003) T-cell-antigen recognition and the immunological
12 synapse. *Nat Rev Immunol* 3(12):973-983.
- 13 48. Bentz GL, *et al.* (2006) Human cytomegalovirus (HCMV) infection of endothelial cells
14 promotes naive monocyte extravasation and transfer of productive virus to enhance
15 hematogenous dissemination of HCMV. *J Virol* 80(23):11539-11555.
- 16 49. Murrell I, *et al.* (2017) The pentameric complex drives immunologically covert cell-cell
17 transmission of wild-type human cytomegalovirus. *Proc Natl Acad Sci U S A*
18 114(23):6104-6109.
- 19 50. Corrales-Aguilar E, *et al.* (2014) Human cytomegalovirus Fcγ binding proteins
20 gp34 and gp68 antagonize Fcγ receptors I, II and III. *PLoS Pathog*
21 10(5):e1004131.
- 22 51. Stanton RJ, *et al.* (2010) Reconstruction of the complete human cytomegalovirus
23 genome in a BAC reveals RL13 to be a potent inhibitor of replication. *J Clin Invest*
24 120(9):3191-3208.
- 25 52. Murrell I, *et al.* (2016) Genetic Stability of Bacterial Artificial Chromosome-Derived
26 Human Cytomegalovirus during Culture In Vitro. *J Virol* 90(8):3929-3943.
- 27 53. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, & Wilkinson GW (2008) Re-
28 engineering adenovirus vector systems to enable high-throughput analyses of gene
29 function. *Biotechniques* 45(6):659-662, 664-658.
- 30 54. Seirafian S (2012) An analysis of human cytomegalovirus gene usage. *PhD thesis,*
31 *Cardiff University* (orca.cf.ac.uk/46644/).
- 32 55. Aoki J, Koike S, Ise I, Sato-Yoshida Y, & Nomoto A (1994) Amino acid residues on
33 human poliovirus receptor involved in interaction with poliovirus. *J Biol Chem*
34 269(11):8431-8438.
- 35 56. Tomasec P, *et al.* (2005) Downregulation of natural killer cell-activating ligand CD155
36 by human cytomegalovirus UL141. *Nat Immunol* 6(2):181-188.
- 37 57. Prod'homme V, *et al.* (2007) The human cytomegalovirus MHC class I homolog UL18
38 inhibits LIR-1+ but activates LIR-1- NK cells. *J Immunol* 178(7):4473-4481.
- 39 58. Wang EC, *et al.* (2002) UL40-mediated NK evasion during productive infection with
40 human cytomegalovirus. *Proc Natl Acad Sci U S A* 99(11):7570-7575.
- 41 59. Cox J & Mann M (2008) MaxQuant enables high peptide identification rates,
42 individualized p.p.b.-range mass accuracies and proteome-wide protein
43 quantification. *Nat Biotechnol* 26(12):1367-1372.
- 44
45

1 **Figure Legends**

2 **Figure 1: HCMV infection down-regulates cell surface CD58**

3 Human fibroblast (HF-TERT) cells infected with **(A)** HCMV strain Merlin or **(B)** strains
4 Merlin or AD169 (MOI=5) or **(A, B)** mock-infected, and analyzed at the indicated time
5 points post-infection by flow cytometry for cell surface expression of CD58 and MHC class-
6 I. clgG = isotype control IgG.

8 **Figure 2: CD58 cell surface down-regulation is mediated by UL148**

9 **(A)** Human fibroblast (HF-TERT) cells infected with a library of HCMV strain Merlin deletion
10 mutants, (MOI=5, 72h post infection) and **(B)** human fibroblast (HF-CAR) cells infected
11 with a library of adenovirus vectors encoding HCMV strain Merlin UL/b' genes, (MOI=5,
12 48h post-infection) as indicated were analyzed by flow cytometry for cell surface
13 expression of CD58 and MHC class-I. MHC class-I down-regulation, which is a standard
14 marker of HCMV infection, was used for quality control. Median fluorescence intensity
15 (MFI) values relative to control cells (set to 1) are shown. **(C, D)** Representative plots from
16 panels **(A)** and **(B)**, respectively. **(E)** Scatterplot of cell surface proteins modulated by
17 UL148 analyzed by plasma membrane profiling. The complete data spreadsheet is shown
18 in S13. Proteins that contained Ig-/ MHC/ Cadherin/ C-type lectin/ TNF InterPro functional
19 domains were included in the scatterplot. Significance B was used to estimate p values
20 (59). The complete data spreadsheet is shown in Dataset S1.

22 **Figure 3: UL148 retains immature CD58 intracellularly and interacts with CD58**

23 Human fibroblast (HF-TERT) cells were infected (MOI=5) with HCMV strain Merlin
24 (HCMV) or a UL148 deletion mutant (Δ UL148) and lysates were analyzed by
25 immunoblotting **(A)** at the indicated time points post-infection or **(B)** 72h post-infection.
26 EndoH or PNGaseF glycosidases were used as indicated. CD155, which is known to be
27 retained in the ER by HCMV UL141 and actin were used as controls. **(C)** HF-TERT cells
28 were infected with HCMV strain Merlin (HCMV) or HCMV recombinants expressing V5-
29 tagged UL148 (HCMVUL148.V5) or UL141 (HCMVUL141.V5) and whole cell lysates
30 (WCL) were analyzed by immunoblotting or co-immunoprecipitation (V5-IP). The known
31 interaction between CD155 and UL141 served as a control.

33 **Figure 4: UL148 modulates CTL function against HCMV-infected cells through CD58**

34 **(A)** Human dermal fibroblast (D007) cells were infected with HCMV strain Merlin (HCMV)
35 or an UL148 deletion mutant (Δ UL148) (MOI=10, 72h). Cells were pulsed with VLE or NLV
36 peptide at 1 μ g/ml and used in standard CD107 degranulation assay as targets for VLE-

1 or NLV-specific T-cell lines generated from donor D007. Means + SEM of quadruplicate
2 samples are shown. **(B)** Expression of CD58 and MHC class-I on D007 cells. **(C)**
3 Summary of HCMV vs HCMV Δ UL148 data from 5 separate experiments standardizing
4 values to the mock-infected control at the peptide concentrations indicated. One-way
5 ANOVA with Tukey (for >5 means) multiple comparison post-hoc tests showed
6 significance differences between HCMV and HCMV Δ UL148 at *** $p < 0.001$. **(D)** Effect of
7 anti-CD58 mAb or an isotype control added at the start of assays to a concentration of
8 10 μ g/ml at the indicated peptide concentrations. Means + SEM of quadruplicate samples
9 are shown. **(E)** Summary data of 3 different blocking experiments following standardization
10 to isotype control values. **(F)** Further blocking assay on uninfected fibroblasts at lower
11 concentrations of peptide pulsing. One-way ANOVA with Tukey (for >5 means) multiple
12 comparison post-hoc tests showed significance differences at ** $p < 0.01$ and *** $p < 0.001$.
13 **(G)** Degranulation of CD3⁺CD8⁺ T-cells in PBMC of 9 HCMV-seropositive donors
14 challenged with autologous fibroblasts infected with HCMV strain Merlin or HCMV Δ UL148
15 in the absence of peptide (MOI=10, 72h). Points are means of triplicate samples. Paired
16 t-Test showed the p value indicated. # marks the 3 of 9 donors showing significant
17 differences ($p < 0.05$) when comparing responses between Merlin and HCMV Δ UL148 using
18 one-way ANOVA with Tukey multiple comparison post-hoc tests with %change from the
19 Merlin response indicated in brackets.


20

21 **Figure 5: Deletion of UL148 alters the response of NK cells**

22 Fibroblasts were infected with HCMV strain Merlin (HCMV) or a UL148 deletion mutant
23 (Δ UL148) (MOI=10, 72h). Cytotect or HCMV-negative IgG was added to a final
24 concentration of 50 μ g/ml. The cells were used to stimulate PBMCs from healthy donors
25 stimulated overnight with 1000 IU/ml IFN α . CD3⁺CD56⁺ NK cell responses to allogeneic
26 fibroblast (HF-TERT) cells from **(A)** a representative donor and **(B)** ten donors comparing
27 responses with control HCMV-negative IgG and Cytotect. CD3⁺CD56⁺ NK cell responses
28 to autologous dermal fibroblasts are shown in **(C)** with a summary of nine donors
29 comparing responses with control HCMV-negative IgG and Cytotect. Allogeneic ADCC
30 responses were further split into **(D)** CD57⁻ and CD57⁺ NK responses, and **(E)** CD57⁻
31 NKG2C⁻, CD57⁺NKG2C⁺ and CD57⁺NKG2C⁻ NK responses in 7 to 9 subjects. Data
32 passed D'Agostino & Pearson omnibus normality testing. Points are mean of triplicate
33 cultures. Paired t-Test showed the indicated significance p values. # marks donors
34 showing significant differences ($p < 0.05$) when comparing individual responses between
35 Merlin and HCMV Δ UL148 using one-way ANOVA with Tukey multiple comparison post-
36 hoc tests. (2C-) indicates NKG2C⁻ subjects, detected by flow cytometry.

1 Figure 1


2




3

4

1 Figure 2




2



1 Figure 4

2




3

4

5

1 Figure 5

2



3

4

5

1 Supplemental Information Legends

2 Figure S1: Details of the library of HCMV recombinants containing single gene 3 deletions

4 Recombinant HCMVs (RCMV) were generated by recombineering of the strain Merlin
5 bacterial artificial chromosome BAC1111/KM192298 (RL13⁻, UL128⁻) (Stanton RJ, *et al.*
6 (2010). *J Clin Invest* 120: 3191-3208). Whole-genome consensus sequences of passage
7 1 of each RCMV were derived by using the Illumina platform as described previously
8 (Fielding CA, *et al.* (2014). *PLoS Pathog* 10: e1004058), and were deposited in GenBank.
9 Deleted regions are shown between slashes in lower case, with the initiation codon
10 underlined, and did not always include the whole protein-coding region. Except for the
11 differences noted, the viruses were genetically identical to that recovered from the parental
12 BAC (RCMV1111/KM192298).

13 * middle G tract near right end of US is 1 bp shorter

14 ** contains an 1190 bp *E. coli* insertion element IS150 plus a 3 bp duplication at the right
15 end inserted into US11. This insertion was considered irrelevant to this study, but the
16 recombinant was not banked for further use and the sequence was not deposited in
17 GenBank.

18

19 Two further recombinants (not listed) were also constructed and their whole-genome
20 sequences verified. To insert a V5 tag after UL148 (RCMV2084), a recombineering
21 cassette comprising KanR/rpsL/lacZ was amplified and inserted into the 5' end of UL148
22 by using primers UL148 SacB Forward
23 GCATTCTCGAGACGTGGCGACGTGGATTTCTTGCTATGTCCGCGAACGACGTGTGA
24 CGAGGACGTGGTTTCCGCAAGCCTCCTGTGACGGAAGATCACTT, UL148 Sac B
25 Reverse

26 TCAACACATTGCTGATTACAATGATGGCGGCGATATGGGCTCGCGTTTTGATAACCT
27 ACCTGGTGTGCGGGCGTCCGGTAGCTGAGGTTCTTATGGCTCTT-3'. In a second
28 round of recombineering, this cassette was removed and replaced by a V5 tag by using
29 the complementary primers
30 TGCTATGTCCGCGAACGACGTGTGACGAGGACGTGGTTTCCGCAAGCCTTTACGTA
31 GAATCAAGACCTAGGAGCGGGTTAGGGATTGGCTTACCAGCGCT

32 And

33 GGCGATATGGGCTCGCGTTTTGATAACCTACCTGGTGTGCGGGCGTCCGAGCGCT
34 GGTAAGCCAATCCCTAACCCGCTCCTAGGTCTTGATTCTACGTAA

35 (V5 tag and linker underlined). To insert a V5 tag after UL141 (RCMV2022), the
36 KanR/rpsL/lacZ was amplified and inserted at the end of UL141 using primers

1 AGGGGACGACGAGGCGGTGAGGGCTATCGACGCCTACCGACTTACGATAGTTACC
2 CCGGTGTTAAAAGATGAAGAGGCCTGTGACGGAAGATCACTTCG and
3 GCATATTTTAATCACACTATTCACATTTTCACACACTGCATTTTTTAACATCTTATTTTT
4 TTATTTTATGCGTGTTCTCACTGAGGTTCTTATGGCTCTTG

5 (regions of homology to UL141 underlined). This cassette was then removed and replaced
6 with a V5 tag, using primers
7 GACGCCTACCGACTTACGATAGTTACCCCGGTGTTAAAAGATGAAGAGGGGCTCC
8 GGGGGGTCTGGGTGGAAGTGGCGGTAAGCCAATCCCTAACCCGCT

9 And
10 ACACACTGCATTTTTTAACATCTTATTTTTTTATTTTATGCGTGTTCTCACGTAGAATC
11 AAGACCTAGGAGCGGGTTAGGGATTGGCTTACCGCCACTTC (complementary
12 regions that overlapped to generate the V5 tag underlined).

13

14 **Figure S2: Transcriptome profiles of HCMV strain Merlin (RCMV1111) and Δ UL148**
15 **(RCMV2035)**

16 **(A)** Whole-cell RNA was isolated from human fibroblast (HF-TERT) cells infected with
17 HCMV strain Merlin (RCMV1111) or a UL148 deletion mutant Δ UL148 (RCMV2035) at 72
18 h post-infection. Transcriptome profiles were derived from directional Illumina RNA-Seq
19 data generated from polyadenylated RNA. The genome is shown in five sections, with the
20 inverted repeats shaded grey. Protein-coding regions and non-coding RNAs are shown by
21 color- and white-shaded arrows, respectively, with gene nomenclature below, and introns
22 as narrow white bars connecting exons. The colours of protein-coding regions indicate
23 conservation among alpha-, beta- and gammaherpesviruses (core genes) or between
24 beta- and gammaherpesviruses (subcore genes), with certain noncore genes grouped into
25 related families. The yellow windows depict transcription profiles for rightward (magenta)
26 and leftward (cyan) transcripts. The extent of transcription is plotted as \log_{10} of the number
27 of reads per nucleotide (calculated by Bowtie2 assembly against the RCMV2035
28 sequence) per million viral reads, the overall number of reads for RCMV2035 being
29 normalised to that for RCMV1111. The number of viral reads (76 nucleotides) in the
30 RCMV1111 and RCMV2035 datasets was 11,857,464 (48% of the total) and 12,178,576
31 (52%), respectively. Among the regions containing zero reads (scored -2) is UL148 in
32 RCMV2035 (boxed). Except for UL148, the transcriptome profile of RCMV2035 was very
33 similar to that of RCMV1111. **(B)** Histogram showing the relative proportion (%) of
34 normalized sequence read counts mapping to individual HCMV protein-coding regions and
35 noncoding RNAs in RCMV2035 compared with RCMV1111. In this experiment, and
36 excluding UL148, transcription levels of the protein-coding regions and non-coding RNAs

1 were 105±16% of those in RCMV1111, ranging from 57% (UL146) to 183% (the region
2 common to IRS1 and TRS1). Only UL148 was differentially expressed >2-fold.

3

4 **Figure S3: Identification of cellular proteins interacting with UL148 via SILAC-IP**

5 SILAC-labelled HFFF-TERT cells were infected (MOI=5, 72h) with unmodified HCMV
6 strain Merlin (light-labeled cells), HCMVUL141.V5 (medium-labeled cells) or
7 HCMVUL148.V5 (heavy-labeled cells) followed by immunoprecipitation of mixed lysates
8 with anti-V5. Enriched proteins were digested with trypsin then subjected to mass
9 spectrometry. To identify proteins that specifically interact with HCMV UL148, the following
10 filters were employed: UL148:wt ratio of >2 and UL148:UL141 ratio of >2. UL141 served
11 as an irrelevant control and did not interact with UL148 (heavy : light ratio = 1.3).
12 Significance A was used to estimate p-values, which were adjusted for multiple hypothesis
13 testing using the method of Benjamini-Hochberg (59).

14

15 **Figure S4: Effect of UL148 on cytokine production**

16 Autologous skin fibroblasts were infected with Merlin (HCMV) or a UL148 deletion mutant
17 (Δ UL148) (MOI =10, 72h) and then used as targets against a CD8⁺ T-cell line or PBMCs.
18 CD107a degranulation and intracellular cytokine staining for IFN γ and TNF α were
19 measured after 6h using standard procedures (Becton Dickinson). **(A, B)** Two separate
20 experiments on a CD8⁺ T-cell line (D009-VTE) at a cognate peptide dose of 1 μ g/ml. **(C)**
21 PBMC data gating on CD57⁺CD3⁻CD56⁺ NK cells with targets in the presence of Cytotect.
22 MFI = median fluorescence intensity for positive cells. Mean + SEM of quadruplicates
23 shown. Two-way ANOVA comparing all means showed significance at *p<0.05, **p<0.01,
24 ***p<0.001.

25

26 **Dataset S1: Mass spectrometric analysis comparing Merlin and Merlin Δ UL148**

27 Excel spreadsheet, no figure legend provided.

28

29

30

1 Supplemental Figure S1


2

GenBank Accession Number	RCMV Serial Number	Deletion
KM192298	RCMV1111	HCMV strain Merlin, parental BAC
KP973627*	RCMV1819*	UL131A ; GAGCAACGAC/acctcggta...acagccgcat/GTTGCAGACT
KP973628	RCMV1821	UL132 ; TCCCAGTCCC/gagtttcaa...ggccggcat/TCTCGAGACG
KP973629	RCMV1823	UL133 ; TCCGATGTCG/gtggggcgg...cgcaaccat/TGCTACTGCG
KP973630	RCMV1825	UL136 ; AGCGACAGCC/gctgcgtag...tgactgacat/ACTCTCTTC
KP973636	RCMV1847	UL138 ; AAGACGATGA/acccgcgcg...gatcgcat/GGTGACCGTC
KP973637	RCMV1849	UL139 ; GCAGCAGCTG/cagactttac...tccacagcat/GTTCGTTACT
KP973638	RCMV1851	UL140 ; AAAAACCAGAG/gtggtcgccc...cgggggcat/GACAAGTCTG
KP973625	RCMV1812	UL142 ; GCCATCCTGA/ggatgtagt...caatccgcat/ATTTAATCA
KP973639	RCMV1853	UL144 ; ATATGTGCGG/tatgatttg...gaggcctcat/GCCTCCTACC
KP973631	RCMV1835	UL145 ; GGAGCATCTC/aacaggcatg...cgccgta cat /CGAAGGCAAC
N.A. **	RCMV1837**	UL146 ; TGATGGGGCG/ataaacatac...ttaatcgcat/TATAATTTTA
KP973626	RCMV1814	UL147 ; CCAGCACTTC/ctgacgattg...ttagcaacat/ATTGAAAACA
KP973640	RCMV1855	UL147A ; ATAGTCTTGC/tcttcgcaa...atagggacat/GATCACCAGC
KP973642	RCMV2035	UL148 ; CCGCAAGCCT/ctaccgacgc...agcgcaacat/GCTGCGCGGG
KP973632	RCMV1839	UL148A ; CGTCTCATCT/tgcccacagc...cggaaactcat/GGCTATCGCC
KP973633*	RCMV1841*	UL148B ; CTAAGGCCGT/gtcgccaacg...ccagcgc cat /CCC GTTCGCT
KP973634	RCMV1843	UL148C ; CCGCGAGCAA/atgttaactc...gacctcgtg/CGTTGTCTCG
KP973635	RCMV1845	UL148D ; GAGTCGCGGC/atgacggcgc...cagcagcagg/CACGCAACGG
KP973641	RCMV1857	UL150/150A ; GTTTGCGGTC/tcggttaagt...gtgtgacat/AGCTGTATGC


3

4

A




B



1 Supplemental Figure S3

2




3


4

5

A D009-VTE expt 1



B D009-VTE expt 2



C D007 - CD3⁺CD56⁺CD57⁺ NK cells vs allogeneic targets + Cytotect

